Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
March 17th 2025, 6:01pm
Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
March 17th 2025, 5:55pm
Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.
Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC
March 17th 2025, 3:27pm
The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups
March 17th 2025, 1:34pm
Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.
Metformin With IUD Boosts Responses in EIN and Endometrial Cancer
March 17th 2025, 1:26pm
Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.
Dr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian Cancer
March 17th 2025, 1:23pm
Jordyn Silverstein, MD, discusses the efficacy of abemaciclib plus hormonal therapy in recurrent ovarian cancer or endometroid endometrial cancer.
Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer
March 16th 2025, 8:59pm
Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.
Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer
March 16th 2025, 7:16pm
Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.
Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer With Low/Medium FRα Expression
March 16th 2025, 6:01pm
Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.
BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer
March 16th 2025, 5:02pm
BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.
Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer
March 16th 2025, 4:50pm
Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.
Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer
March 16th 2025, 4:40pm
Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.
Avutometinib With Defactinib Exceeds Response Threshold in Advanced Mesonephric Gynecologic Cancer
March 16th 2025, 4:17pm
The combination of avutometinib and defactinib has previously shown activity in patients with low-grade serous ovarian cancer.
Pembrolizumab Plus Olaparib Improves PFS in BRCA Wild-Type Ovarian Cancer
March 16th 2025, 3:50pm
The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.
Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer
March 16th 2025, 11:05am
Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.
Dr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
March 16th 2025, 10:24am
Toon Van Gorp, MD, PhD, discusses the efficacy of mirvetuximab soravtansine in FRα-positive platinum-resistant ovarian cancer after 30.5 months of follow-up.
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
March 15th 2025, 8:15pm
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
March 15th 2025, 8:05pm
Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
March 15th 2025, 4:40pm
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer
March 15th 2025, 4:00pm
The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.